# Adjuvant Vinorelbine Plus Cisplatin(NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer(NSCLC)

> **NCT01124253** · PHASE3 · COMPLETED · sponsor: **Shanghai Jiao Tong University School of Medicine** · enrollment: 250 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** recombinant human endostatin

## Key facts

- **NCT ID:** NCT01124253
- **Lead sponsor:** Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2010-05-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01124253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01124253, "Adjuvant Vinorelbine Plus Cisplatin(NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer(NSCLC)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01124253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*